Log In
Print
BCIQ
Print
Print this Print this
 

EZN-2279

  Manage Alerts
Collapse Summary General Information
Company Sigma-Tau Group
DescriptionPegylated recombinant adenosine deaminase
Molecular Target
Mechanism of ActionEnzyme replacement therapy
Therapeutic ModalityBiologic: Enzyme
Latest Stage of DevelopmentPhase III
Standard Indication Metabolic (unspecified)
Indication DetailsTreat adenosine deaminase deficiency in patients with severe combined immune deficiency (SCID)
Regulatory Designation

U.S. - Orphan Drug (Treat adenosine deaminase deficiency in patients with severe combined immune deficiency (SCID))

Partner

Teijin Pharma Ltd.


 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today